Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Up 5.3% in July

Posted by Defense World Staff on Aug 1st, 2023

Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Get Free Report) saw a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 921,200 shares, a growth of 5.3% from the June 30th total of 875,200 shares. Based on an average trading volume of 107,400 shares, the days-to-cover ratio is currently 8.6 days.

Wall Street Analysts Forecast Growth

MIST has been the subject of several research analyst reports. Oppenheimer cut their price objective on Milestone Pharmaceuticals from $16.00 to $13.00 and set an “outperform” rating for the company in a report on Wednesday, April 12th. Jefferies Financial Group lowered Milestone Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their target price for the stock from $8.00 to $4.00 in a research report on Tuesday, June 20th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SA acquired a new position in shares of Milestone Pharmaceuticals during the first quarter worth about $25,000. PDT Partners LLC acquired a new position in shares of Milestone Pharmaceuticals during the first quarter worth about $65,000. Cubist Systematic Strategies LLC acquired a new position in shares of Milestone Pharmaceuticals during the third quarter worth about $107,000. Virtu Financial LLC bought a new stake in Milestone Pharmaceuticals during the second quarter worth about $33,000. Finally, Engineers Gate Manager LP bought a new stake in Milestone Pharmaceuticals during the third quarter worth about $108,000. 64.43% of the stock is owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Price Performance

Shares of MIST stock opened at $3.23 on Tuesday. The stock’s fifty day simple moving average is $3.51 and its 200 day simple moving average is $3.64. The company has a debt-to-equity ratio of 0.88, a current ratio of 13.63 and a quick ratio of 13.63. The firm has a market cap of $107.75 million, a price-to-earnings ratio of -2.32 and a beta of 1.86. Milestone Pharmaceuticals has a one year low of $2.73 and a one year high of $9.85.

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last issued its quarterly earnings data on Thursday, May 11th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.03. The business had revenue of $1.00 million during the quarter. On average, analysts expect that Milestone Pharmaceuticals will post -1.51 earnings per share for the current fiscal year.

Milestone Pharmaceuticals Company Profile

(Get Free Report)

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.